News Releases

Bodisen Biotech, Inc. Financials
Income Statement

Quarterly Data

All numbers in thousands

PERIOD ENDING

31-Dec-04

30-Sep-04

30-Jun-04

31-Mar-04

Total Revenue

4,402  

5,408  

4,230  

2,186  

Cost of Revenue

2,709  

3,389  

2,243  

1,313  

Gross Profit

1,693  

2,019  

1,987  

873  

 
 

Operating Expenses

 

Research Development

-  

-  

-  

-  

 

Selling General and Administrative

533  

406  

234  

350  

 

Non Recurring

-  

-  

-  

-  

 

Others

-  

-  

-  

-  

   
 

Total Operating Expenses

-  

-  

-  

-  

 

Operating Income or Loss

1,160  

1,613  

1,753  

523  

 
 

Income from Continuing Operations

 

Total Other Income/Expenses Net

41  

4  

8  

-  

 

Earnings Before Interest And Taxes

1,201  

1,617  

1,761  

523  

 

Interest Expense

16  

20  

11  

27  

 

Income Before Tax

1,186  

1,597  

1,750  

495  

 

Income Tax Expense

-  

-  

(74)

74  

 

Minority Interest

-  

-  

-  

-  

   
 

Net Income From Continuing Ops

1,186  

1,597  

1,824  

421  

 
 

Non-recurring Events

 

Discontinued Operations

-  

-  

-  

-  

 

Extraordinary Items

-  

-  

-  

-  

 

Effect Of Accounting Changes

-  

-  

-  

-  

 

Other Items

-  

-  

-  

-  

 

Net Income

1,186  

1,597  

1,824  

421  

Preferred Stock And Other Adjustments

-  

-  

-  

-  

Net Income Applicable To Common Shares

$1,186  

$1,597  

$1,824  

$421 

 

Copyright © 2004 bodisen.com